이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

2세 이상 인도 참가자의 P. Vivax 말라리아 치료를 위해 타페노퀸(TQ)과 프리마퀸(PQ)을 클로로퀸(CQ)과 함께 복용할 때의 효능과 안전성을 비교하기 위한 중재 연구

2026년 9월 28일 업데이트: GlaxoSmithKline

효능에 대한 무작위, 공개 라벨, 다기관, 중재 3상 연구. 인도 참가자(소아 및 성인 인구)의 Plasmodium Vivax(P. Vivax) 말라리아의 근본적인 치료(재발 예방)에 대한 Primaquine(둘 다 클로로퀸과 병용)과 비교한 Tafenoquine의 안전성

The aim of this study is to collect efficacy and safety data to support the registration of tafenoquine in India.

연구 개요

연구 유형

중재적

등록 (추정된)

324

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

      • Ahmedabad, 인도, 380008
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Leena Dabhi
      • Bikaner, 인도, 334001
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Sanjay Kumar Kochar
      • Kolkata, 인도, 700073
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Arunansu Talukdar
      • Mumbai, 인도, 400012
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Nithya Gogtay
      • Surat, 인도, 395004
        • 모병
        • GSK Investigational Site
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Shailesh Jethwa

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

2년 (어린이, 성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Males and females >=2 years of age and under (<) 65 years of age, weighing >10 kg.

  2. The participant has a positive malarial smear for P. vivax with a parasite density of >100/microliter and <100,000/microliter.

  3. The participant has a screening Hb value >8 g/dL.

  4. The participant has an axillary temperature of 37.5°C or history of fever 48 hours before recruitment.

  5. The participant has a G6PD value (measured using the SD Biosensor STANDARDTM G6PD test) 6.1 units/gram (U/g) Hb for G6PD activity (6.1 U/g Hb cut-off is applicable for both males and females).

  6. A female participant is eligible to participate if she is not pregnant or breastfeeding, and if one of the following conditions applies:

    • Is a woman of non-childbearing potential (WONCBP) as defined in
    • Is a Women of Childbearing Potential (WOCBP) and using a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency, during the study intervention period and for at least 90 days after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the first dose of study intervention. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
  7. A WOCBP must test negative on a highly sensitive pregnancy test (urine or serum as required by local regulations) before the first dose of study intervention.

  8. The participant is willing and able to comply with the procedures described in the study protocol. The participant or parent/legal guardian, as applicable, has given written informed, dated consent; and the participant has given written assent, if applicable, to participate in the study.

Exclusion Criteria:

  1. The participant has severe P. vivax malaria as defined by WHO criteria [WHO, 2023].

  2. The participant has a mixed malaria infection (identified by a malarial smear).

  3. The participant has a condition that may affect absorption of study medication, such as severe vomiting (no food or inability to take food during the previous 8 hours).

  4. The participant has a history of porphyria, psoriasis, or epilepsy.

  5. The participant has a history of allergy, intolerance to or a known contraindication to the use of mefloquine (or other aryl amino alcohol drugs), chloroquine, tafenoquine, primaquine, any other 4- or 8-AQ or any of their respective excipients.

  6. The participant has received treatment with any investigational drug within 30 days of study entry, or within 5 half-lives, whichever is longer.

  7. The participant has previously enrolled in this study.

  8. The participant has a recent history of illicit drug abuse or heavy alcohol intake that in the opinion of the investigator could compromise full participation in the study or adherence to study procedures.

  9. Participants with a current or past history of serious psychiatric disorders.

  10. The participant has a clinically significant concurrent illness (e.g., pneumonia, tuberculosis, meningitis, septicemia, dengue, coagulopathy, severe hemorrhage, or febrile convulsions prior to consent) or a pre-existing condition (e.g., renal disease, malignancy, or severe malnutrition according to WHO child growth standards) or systemic disease predisposing patients to suffer from granulocytopenia, such as rheumatoid arthritis and lupus erythematosus or severe ocular disease.

  11. The participant is known to be HIV-infected and/or is currently on antiretroviral therapy.

  12. The participant is regularly using drugs with hemolytic potential.

  13. The participant has a QT corrected by Fridericia's formula (QTcF) >450 msec, evidence of bradycardia (<50 beats per min) or ventricular arrhythmias on the screening ECG, a history of cardiac disease (e.g., myocardial infarction, congenital heart disease, or arrhythmia), hypokalemia (<2.9 millimoles per liter [mmol/L]) or hyperkalemia (>=6.0 mmol/L) at Screening.

  14. The participant has taken drugs with antimalarial activity (e.g., artemisinin-based combination therapies, mefloquine, primaquine, chloroquine, tafenoquine or any other 4-AQ) within 30 days prior to study entry.

  15. The participant has taken or will likely require during the study the use of:

    1. Histamine-2 blockers (restricted to first 3 days whilst receiving CQ)
    2. Antacids (restricted to first 3 days whilst receiving CQ)
    3. Drugs of the biguanide class (i.e., phenformin, metformin, buformin)
    4. Anti-arrhythmic agents (i.e., dofetilide, procainamide, pilsicainide)
    5. Medications that prolong the QTc interval
  16. The participant has liver transaminases (ALT/AST) >2 times the upper limit of normal (ULN).

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: TQ/CQ

Participants in this group receive a single dose of TQ on Day 1 or Day 2 and a single dose of CQ daily, on Days 1 to 3.

A single dose of TQ will be administered orally on Day 1 or Day 2.

A single dose of CQ will be administered orally, daily, on Days 1 to 3.

활성 비교기: PQ/CQ

Participants in this group receive a single dose of PQ daily from Day 1 or 2, up to Day 14 (or Day 15 if PQ started on Day 2) and a single dose of CQ daily, on Days 1 to 3.

A single dose of CQ will be administered orally, daily, on Days 1 to 3.

A single dose of PQ will be administered orally, daily, on Day 1 or 2 to Day 14 (or Day 15 if PQ started on Day 2).

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Number of participants remaining recurrence-free during the 6 months post-treatment and have a negative blood smear at the Month 6 (end of study [EOS]) visit
기간: Up to Month 6

Two consecutive negative blood smears between Day 2 and Day 8, no positive blood smear for P. vivax parasites at any point during the 6-month follow-up period, and a negative P. vivax smear at the 6-month assessment.

Up to Month 6

2차 결과 측정

결과 측정
측정값 설명
기간
사망자 수
기간: 6개월까지
6개월까지
>= AIDS(DAIDs) 3등급 기준을 충족하는 실험실 매개변수
기간: 6개월까지
6개월까지
>=DAID 3등급 기준을 충족하는 활력징후 매개변수
기간: 6개월까지
6개월까지
각 연구 방문 시 혈액학 매개변수에 대한 기준선 대비 변화(망상적혈구 백분율)
기간: 5, 8, 15, 29, 60, 90, 120, 150 및 180일
5, 8, 15, 29, 60, 90, 120, 150 및 180일
Number of participants with clinically relevant hemolysis change from baseline
기간: Up to Day 14

A decrease in hemoglobin of greater than or equal to (>=) 30% or greater than (>) 3g/deciliter (dL) from baseline; or an overall drop in hemoglobin below 6.0 g/dL or complications thereof (e.g., required transfusions, acute renal failure) are considered clinically relevant hemolysis changes.

Up to Day 14
Time to recurrence of P. vivax malaria
기간: Up to Month 6

Recurrence is defined as a positive blood smear for P. vivax parasites within the 6-month follow-up period, after clearance of blood-stage parasitemia.

Up to Month 6
Number of participants with treatment emergent adverse events (TEAEs) up to Month 6
기간: Up to Month 6

An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to Month 6
Number of participants with TEAEs meeting >= Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 criteria
기간: Up to Month 6

Severity was graded according to DAIDS grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening, Grade 5-Death.

Up to Month 6
Number of participants with drug related TEAEs
기간: Up to Month 6

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to Month 6
Number of participants with serious AEs (SAEs)
기간: Up to Month 6

A SAE is any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization or result in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant.

Up to Month 6
Number of participants with AEs resulting in treatment discontinuation
기간: Up to Month 6

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to Month 6
Number of participants with AEs leading to study withdrawal
기간: Up to Month 6

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to Month 6
Number of participants with AEs considered to be hematologically related
기간: Up to Month 6

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to Month 6
Liver chemistry changes meeting Hy's criteria
기간: Up to Month 6

Hy's criteria cases were defined as any elevated alanine aminotransferase (ALT) >=3 times upper limit of normal (ULN) and total bilirubin >=2 times ULN or ALT >=3 times ULN and international normalized ratio (INR) >1.5.

Up to Month 6
Number of participants with TEAEs up to Week 4
기간: Up to Week 4

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to Week 4
Change from baseline at each study visit for clinical chemistry parameters (ALT, AST, ALP)
기간: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Data for alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) is measured in international units/liter (IU/L).

At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
Change from baseline at each study visit for clinical chemistry parameters (CPK)
기간: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Data for creatine phosphokinase (CPK) is measured in units per liter (U/L).

At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
Change from baseline at each study visit for clinical chemistry parameters (total bilirubin, indirect bilirubin, blood urea nitrogen [BUN]/Urea, and serum creatinine)
기간: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Clinical chemistry parameters are measured in milligrams per decilitre (mg/dL).

At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
Change from baseline at each study visit for clinical chemistry parameters (serum electrolytes)
기간: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Data for serum electrolytes is measured in millimoles per liter (mmol/L).

At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
Change from baseline at each study visit for haematology parameters (platelet count)
기간: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Platelets are measured in number of platelets per microliter (µL).

At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
Change from baseline at each study visit for haematology parameters (red blood cell [RBC] count)
기간: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Data for RBC is measured in millions of cells per microliter (number of RBCs x10^6/µL).

At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
Change from baseline at each study visit for haematology parameters (mean corpuscular volume [MCV])
기간: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Data for MVC is measured in femtoliters (fL).

At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
Change from baseline at each study visit for haematology parameters (mean corpuscular hemoglobin [MCH])
기간: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Data for MCH is measured in picograms (pg) per cell.

At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
Change from baseline at each study visit for haematology parameters (white blood cell count [WBC] with differential)
기간: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Data for neutrophils, lymphocytes, monocytes, eosinophils and basophils is presented as a count, which measures a percentage (%) of the WBC.

At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
Change from baseline at each study visit for haematology parameters (hemoglobin)
기간: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Hemoglobin is measured in grams per deciliter (g/dL).

At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
Change from baseline at each study visit for haematology parameters (hematocrit)
기간: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Hematocrit is measured in volume percentage (%) of RBC in blood.

At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 11월 13일

기본 완료 (추정된)

2027년 5월 14일

연구 완료 (추정된)

2027년 5월 14일

연구 등록 날짜

최초 제출

2024년 10월 18일

QC 기준을 충족하는 최초 제출

2024년 10월 29일

처음 게시됨 (실제)

2024년 10월 30일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 1일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 28일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

IPD 공유 기간

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

IPD 공유 액세스 기준

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다